Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
IGT
MCID: PRD004
MIFTS: 56

Prediabetes Syndrome (IGT)

Categories: Blood diseases, Endocrine diseases, Genetic diseases, Metabolic diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Prediabetes Syndrome

About this section

MalaCards integrated aliases for Prediabetes Syndrome:

Name: Prediabetes Syndrome 11 14 16 71
Prediabetes 11 41 14 75
Impaired Glucose Tolerance 11 53 33
Prediabetic State 11 53 43
Impaired Glucose Tolerance with Unspecified Complication 33
Impaired Glucose Tolerance Without Complication 33
Igt - [impaired Glucose Tolerance] 33
Abnormal Glucose Tolerance 33
Igt 47

Classifications:

MalaCards categories:
Global: Metabolic diseases Genetic diseases
Anatomical: Endocrine diseases Blood diseases
See all MalaCards categories (disease lists)
ICD11: 33


External Ids:

Disease Ontology 11 DOID:11716
MeSH 43 D011236
NCIt 49 C122685
SNOMED-CT 68 15777000
ICD11 33 1085399840
UMLS 71 C0362046
Sources

Summaries for Prediabetes Syndrome

About this section

MedlinePlus: 41 What is prediabetes? Prediabetes means that your blood glucose, or blood sugar, levels are higher than normal but not high enough to be called diabetes. Glucose comes from the foods you eat. Too much glucose in your blood can damage your body over time. If you have prediabetes, you are more likely to develop type 2 diabetes, heart disease, and stroke. But if you make some lifestyle changes now, you may be able to delay or prevent type 2 diabetes. What causes prediabetes? Prediabetes usually happens when your body has a problem with insulin. Insulin is a hormone that helps the glucose get into your cells to give them energy. A problem with insulin could be: Insulin resistance, a condition in which the body can't use its insulin properly. It makes it hard for your cells to get glucose from your blood. This can cause your blood sugar levels to rise. Your body can't make enough insulin to keep your blood sugar levels at a healthy level Researchers think that being overweight and not getting regular physical activity are major factors in causing prediabetes. Who is at risk for prediabetes? About 1 out of every 3 adults has prediabetes. It is more common in people who: Are overweight or have obesity Are age 45 or older Have a parent, brother, or sister with diabetes Are African American, Alaska Native, American Indian, Asian American, Hispanic/Latino, Native Hawaiian, or Pacific Islander American Are not physically active Have health conditions such as high blood pressure and high cholesterol Have had gestational diabetes (diabetes in pregnancy) Have a history of heart disease or stroke Have metabolic syndrome Have polycystic ovary syndrome (PCOS) What are the symptoms of prediabetes? Most people don't know they have prediabetes because usually there are no symptoms. Some people with prediabetes may have darkened skin in the armpit or on the back and sides of the neck. They may also have many small skin growths in those same areas. How is prediabetes diagnosed? There are a few different blood tests that can diagnose prediabetes. The most common ones are: Fasting plasma glucose (FPG) test, which measures your blood sugar at a single point in time. You need to fast (not eat or drink) for at least 8 hours before the test. The results of the test are given in mg/dL (milligrams per deciliter): A normal level is 99 or below Prediabetes is 100 to 125 Type 2 diabetes is 126 and above A1C test, which measures your average blood sugar over the past 3 months. The results of an A1C test are given as a percentage. The higher the percentage, the higher your blood sugar levels have been. A normal level is below 5.7% Prediabetes is between 5.7 to 6.4% Type 2 diabetes is above 6.5% If I have prediabetes, will I get diabetes? If you have prediabetes, you may be able to delay or prevent type 2 diabetes through lifestyle changes: Losing weight, if you are overweight Getting regular physical activity Following a healthy, reduced-calorie eating plan In some cases, your health care provider may also recommend taking diabetes medicines. Can prediabetes be prevented? If you are at risk for prediabetes, those same lifestyle changes (losing weight, regular physical activity, and a healthy eating plan) may prevent you from getting it. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary: Prediabetes Syndrome, also known as prediabetes, is related to glucose intolerance and type 1 diabetes mellitus. An important gene associated with Prediabetes Syndrome is INS (Insulin), and among its related pathways/superpathways are Signal Transduction and PI3K-Akt signaling pathway. The drugs Curcumin and Orlistat have been mentioned in the context of this disorder. Affiliated tissues include ovary, heart and kidney, and related phenotypes are homeostasis/metabolism and growth/size/body region

Disease Ontology: 11 A glucose metabolism disease that is characterized by blood glucose levels are high, but not high enough to be classified as type 2 diabetes.

Wikipedia: 75 Prediabetes is a component of the metabolic syndrome and is characterized by elevated blood sugar levels... more...
Sources

Related Diseases for Prediabetes Syndrome

About this section

Diseases related to Prediabetes Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 681)
# Related Disease Score Top Affiliating Genes
1 glucose intolerance 32.4 SLC2A4 RETN RBP4 PPARG LEP IRS1
2 type 1 diabetes mellitus 31.7 RBP4 LEP INS IGF1 IAPP GHRL
3 hypertriglyceridemia 1 31.6 SERPINE1 INS APOB
4 coronary heart disease 1 31.5 SERPINE1 INS CRP APOB ADIPOQ
5 abdominal obesity-metabolic syndrome 1 31.4 SLC2A4 SERPINE1 RETN PPARG LEP INS
6 hypercholesterolemia, familial, 1 31.4 INS CRP APOB
7 type 2 diabetes mellitus 31.4 SLC2A4 SERPINE1 RETN RBP4 PPARG LEP
8 atherosclerosis susceptibility 31.4 SERPINE1 RETN PPARG LEP INS CRP
9 hyperinsulinism 31.4 SLC2A4 SERPINE1 RETN PPARG LEP IRS1
10 arteries, anomalies of 31.3 INS CRP APOB ADIPOQ
11 hyperglycemia 31.3 SERPINE1 RETN PPARG LEP IRS1 INSR
12 cardiovascular system disease 31.3 SERPINE1 RETN PPARG LEP INS IGF1
13 diabetes mellitus 31.3 SLC2A4 SERPINE1 RETN RBP4 PPARG LEP
14 peripheral vascular disease 31.3 SERPINE1 INS CRP APOB
15 peripheral nervous system disease 31.3 PPARG LEP INS IGF1 GCG DPP4
16 gestational diabetes 31.3 SLC2A4 RETN RBP4 PPARG LEP IRS1
17 hypoglycemia 31.3 SLC2A4 LEP INSR INS IGF1 IAPP
18 leptin deficiency or dysfunction 31.2 SLC2A4 RETN RBP4 PPARG LEP IRS1
19 lipoprotein quantitative trait locus 31.2 SERPINE1 RETN PPARG IRS1 INS GCG
20 cystic fibrosis 31.2 RBP4 PPARG LEP INS IGF1 CRP
21 polycystic ovary syndrome 31.1 SLC2A4 SERPINE1 RETN PPARG LEP IRS1
22 heart disease 31.1 SERPINE1 RETN RBP4 PPARG INS IGF1
23 acanthosis nigricans 31.1 SLC2A4 LEP INSR INS IGF1 ADIPOQ
24 vascular disease 31.1 SERPINE1 RETN RBP4 PPARG LEP INS
25 acute myocardial infarction 31.1 SERPINE1 RETN INS CRP APOB
26 coronary stenosis 31.1 SERPINE1 CRP APOB
27 intermediate coronary syndrome 31.1 INS DPP4 CRP APOB
28 lipid metabolism disorder 31.1 SLC2A4 SERPINE1 RETN RBP4 PPARG LEP
29 non-alcoholic fatty liver disease 31.1 SERPINE1 RETN RBP4 PPARG LEP IRS1
30 familial hyperlipidemia 31.1 SERPINE1 PPARG LEP INS GCK CRP
31 nutritional deficiency disease 31.1 RETN RBP4 LEP IGF1 GHRL CRP
32 pre-eclampsia 31.0 SERPINE1 LEP INS IGF1 CRP ADIPOQ
33 acromegaly 31.0 LEP INS IGF1 GHRL ADIPOQ
34 liver disease 31.0 RETN RBP4 PPARG LEP IRS1 INSR
35 hyperandrogenism 31.0 RETN PPARG INSR INS IGF1 CAPN10
36 liver cirrhosis 31.0 SLC2A4 RETN RBP4 LEP INSR INS
37 amyloidosis 31.0 RBP4 INS IAPP CRP
38 insulinoma 31.0 INS IAPP GCK GCG GAD1
39 turner syndrome 31.0 LEP INS IGF1
40 alcohol dependence 31.0 PPARG LEP INS GHRL GAD1
41 apnea, obstructive sleep 30.9 RETN LEP INS IGF1 GHRL GCG
42 chronic kidney disease 30.9 RBP4 LEP INS IGF1 GHRL CRP
43 sleep apnea 30.9 SERPINE1 RETN PPARG LEP INS IGF1
44 non-alcoholic steatohepatitis 30.8 PPARG LEP INS GCG APOB ADIPOQ
45 beta-thalassemia 30.8 LEP INS IGF1 CRP APOB
46 sleep disorder 30.8 LEP INS IGF1 GHRL CRP ADIPOQ
47 schizophrenia 30.8 PPARG LEP INS IGF1 GHRL GAD1
48 insulin-like growth factor i 30.8 LEP IRS1 INSR INS IGF1 GHRL
49 hypopituitarism 30.8 LEP INS IGF1 CRP
50 hyperthyroidism 30.8 RETN LEP INS IGF1 GHRL CRP

Graphical network of the top 20 diseases related to Prediabetes Syndrome:



Diseases related to Prediabetes Syndrome
Sources

Symptoms & Phenotypes for Prediabetes Syndrome

About this section

GenomeRNAi Phenotypes related to Prediabetes Syndrome according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.19 ADIPOQ APOB CAPN10 CRP DPP4 GAD1
2 no effect GR00402-S-2 10.19 ADIPOQ APOB CRP DPP4 GAD1 GCG

MGI Mouse Phenotypes related to Prediabetes Syndrome:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.48 ADIPOQ APOB CAPN10 CRP DPP4 GAD1
2 growth/size/body region MP:0005378 10.36 ADIPOQ APOB CAPN10 DPP4 GAD1 GCG
3 endocrine/exocrine gland MP:0005379 10.31 ADIPOQ CAPN10 DPP4 GAD1 GCG GCK
4 muscle MP:0005369 10.3 ADIPOQ APOB IGF1 INS INSR IRS1
5 liver/biliary system MP:0005370 10.29 ADIPOQ APOB CAPN10 GCK INS INSR
6 renal/urinary system MP:0005367 10.28 ADIPOQ CAPN10 GCG GCK IGF1 INS
7 adipose tissue MP:0005375 10.27 ADIPOQ CAPN10 GHRL IGF1 INS INSR
8 cardiovascular system MP:0005385 10.2 ADIPOQ APOB CAPN10 CRP DPP4 GCK
9 cellular MP:0005384 10.18 ADIPOQ APOB DPP4 GAD1 GCK IGF1
10 immune system MP:0005387 10.16 ADIPOQ APOB CAPN10 CRP DPP4 IAPP
11 digestive/alimentary MP:0005381 10.01 GAD1 GCG GHRL INS INSR LEP
12 skeleton MP:0005390 9.85 ADIPOQ CAPN10 GAD1 IAPP IGF1 INS
13 hematopoietic system MP:0005397 9.77 ADIPOQ CAPN10 DPP4 GCK IAPP IGF1
14 mortality/aging MP:0010768 9.47 ADIPOQ APOB DPP4 GAD1 GCG GCK
Sources

Drugs & Therapeutics for Prediabetes Syndrome

About this section

Drugs for Prediabetes Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 434)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Curcumin Approved, Investigational Phase 4 458-37-7, 84765-67-3 969516
2
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
3
Ethanol Approved Phase 4 64-17-5 702
4
Rosiglitazone Approved, Investigational Phase 4 122320-73-4, 155141-29-0 77999
5
Pravastatin Approved Phase 4 81093-37-0 54687
6
Fluspirilene Approved, Investigational Phase 4 1841-19-6 3396
7
Pitavastatin Approved Phase 4 147511-69-1 5282452
8
Phylloquinone Approved, Investigational Phase 4 84-80-0 5284607
9
Nitric Oxide Approved Phase 4 10102-43-9 145068
10
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
11
Nateglinide Approved, Investigational Phase 4 105816-04-4 60026
12
Bilberry Approved, Experimental Phase 4
13
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
14
Nebivolol Approved, Investigational Phase 4 152520-56-4, 99200-09-6, 118457-14-0 71301
15
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068
16
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
17
Morphine Approved, Investigational Phase 4 57-27-2 5288826
18
Methyltestosterone Approved Phase 4 58-18-4 6010
19
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0 21873174 65157
20
Testosterone enanthate Approved Phase 4 315-37-7 9416
21
Testosterone Approved, Investigational Phase 4 58-22-0 5408 6013
22
Empagliflozin Approved Phase 4 864070-44-0 73151030 11949646
23
Mirabegron Approved Phase 4 223673-61-8 18319735 9865528
24
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
25
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
26
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
27
Atorvastatin Approved Phase 4 134523-00-5 60823
28
Bromocriptine Approved, Investigational, Withdrawn Phase 4 25614-03-3 31101
29
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
30
Suvorexant Approved, Investigational Phase 4 1030377-33-3 57505028 24965990
31
Promethazine Approved, Investigational Phase 4 60-87-7 4927
32
Dapagliflozin Approved Phase 4 461432-26-8 9887712
33
Saxagliptin Approved Phase 4 361442-04-8 11243969
34
Amlodipine Approved Phase 4 88150-42-9 2162
35
Acarbose Approved, Investigational Phase 4 56180-94-0 441184 444254
36
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
37
Sildenafil Approved, Investigational Phase 4 139755-83-2, 171599-83-0 5212 135398744
38
Quinapril Approved, Investigational Phase 4 82586-55-8, 85441-61-8 54892
39
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523
40
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
41
Lipoic acid Approved, Investigational, Nutraceutical Phase 4 1200-22-2 864 6112
42 Kava Approved, Investigational, Nutraceutical Phase 4 9000-38-8
43
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
44
Metadoxine Experimental Phase 4 74536-44-0
45 Menaquinone Investigational Phase 4 1182-68-9
46
Menatetrenone Investigational Phase 4 56973-41-2, 863-61-6 5282367
47
Betadex Experimental Phase 4 7585-39-9 320761
48 Anesthetics Phase 4
49 Adrenergic alpha-Agonists Phase 4
50 Trace Elements Phase 4

Interventional clinical trials:

(show top 50) (show all 1017)
# Name Status NCT ID Phase Drugs
1 Effect of Oral Supplementation With Curcumin on Insulin Sensitivity in Subjects With Prediabetes Unknown status NCT03917784 Phase 4 Curcumin;Starch
2 A Multi-center, Open-label, Randomized, 12-month, Parallel-group, Non-inferiority Study to Compare the Hemoglobin A1C Metabolism of Pitavastatin Therapy Versus Atorvastatin in Chinese Patients With Prediabetes and Hypertension Unknown status NCT03532620 Phase 4 Pitavastatin Calcium;Atorvastatin Calcium
3 Effect of Saxagliptin on Body Fat , Glucose and Beta Cell Function in Patients With Newly Diagnosed Pre-Diabetes Mellitus and Obesity Unknown status NCT01960205 Phase 4 Saxagliptin;saxagliptin;metformin
4 Metformin Administration Effect Over Systemic Inflammation Serum Markers in HIV Positive Prediabetic Patients Unknown status NCT03774108 Phase 4 Metformin Hydrochloride 850 MG
5 Hospital-based Diabetes Prevention Study in Korea: A Prospective, Multi-center, Randomized, Open-label Controlled Study Unknown status NCT02981121 Phase 4 Metformin
6 Intensity of Exercise and Glucose Metabolism Unknown status NCT01649219 Phase 4
7 Multicenter Trial on Clinical Utility of Acarbose in Patients With Ischemic Heart Disease Accompanied by Abnormal Glucose Regulation Unknown status NCT00858676 Phase 4 acarbose
8 Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance Unknown status NCT00733174 Phase 4 Rosiglitazone;Placebo
9 Research of Intensive Metabolic Intervention Before Pregnancy in Polycystic Ovary Syndrome Unknown status NCT03383068 Phase 4 Acarbose 100 MG;Exenatide;Orlistat;Metformin
10 Antiatherogenic and Antimetabolic Effect of Curcumin Therapy in the Prevention and Delay of Type 2 Diabetic in Patients With Impaired Glucose Tolerance and Insulin Resistance Unknown status NCT01052025 Phase 4 Curcumin
11 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Fatty Liver Disease Prediabetic Mexican Patients Unknown status NCT02051842 Phase 4 Metadoxine
12 The Efficacy of a Once Weekly Glucagon-Like Peptide-1 Agonist on Body Weight/Composition and Metabolic Parameters in Persons With SCI Unknown status NCT03292315 Phase 4 Exenatide 2 MG Injection [Bydureon]
13 The Research About the Influence of Medical Interventions in the Period of Insulin Resistance on Prevalence of Abnormal Glucose Tolerance Unknown status NCT02502344 Phase 4 Metformin
14 Effect of Dapagliflozin on Blood Pressure Variability in Patients With Prediabetes and Prehypertension Without Pharmacological Treatment Completed NCT03006471 Phase 4 Dapagliflozin;Placebo - Cap
15 Effects of Physical Exercise Versus Rosiglitazone on Endothelial Function in Coronary Artery Disease Patients With Prediabetes Completed NCT00675740 Phase 4 rosiglitazone
16 Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes Completed NCT02700334 Phase 4 Dapagliflozin;Placebo
17 Effect of Linagliptin + Metformin vs Metformin Alone on the Role of Pancreatic Islet Function, Insulin Resistance and Markers of Cardiovascular Risk in Patients With Prediabetes: Randomized Clinical Trial Completed NCT03004612 Phase 4 Metformin
18 Effect of Pravastatin in the Subjects With Prediabetes or Early Diabetes Completed NCT02754739 Phase 4 Pravastatin;Placebo (for Pravastatin)
19 Jom Mama Project - Pre-pregnancy Intervention to Reduce the Risk of Diabetes and Prediabetes Completed NCT02617693 Phase 4
20 Effect of Rubus Occidentalis Extract on Plasma Glucose Levels in Subject With Prediabetes; A Proof-of-concept, Randomized, Double-blind, Parallel-group Placebo-controlled Study Completed NCT01964703 Phase 4 Rubus occidentalis extract
21 Effect of Linagliptin + Metformin on Glucose Metabolism and Pancreatic Beta Cell Function in Patients With Prediabetes Who do Not Achieve Normoglycemia After 12 Months of Treatment With Metformin Alone Completed NCT04088461 Phase 4 Linagliptin / Metformin Oral Tablet;Metformin
22 Coronary Artery Disease Progression by iMap Intravascular Ultrasound Analysis in Patients With Prediabetes Completed NCT02744976 Phase 4 Metformin
23 Comparative Effects of Antidiabetic Medications on Postprandial Hyperlipidemia, Free Fatty Acid Signaling, and Endothelial Dysfunction in Individuals With Prediabetes Completed NCT02104739 Phase 4 Exenatide;Saxagliptin;Exenatide extended-release (ER)
24 Improving Beta Cell Function in Mexican American Women With Prediabetes Completed NCT02488057 Phase 4 Liraglutide
25 Diet and Exercise in Type 2 Diabetes and Prediabetes Completed NCT00928005 Phase 4
26 The Effect of Metformin on Clinical Course of Ischemic Etiology Chronic Heart Failure in Patients With Prediabetes: the Open-label Randomized Clinical Trial Completed NCT04549415 Phase 4 Metformin Hydrochloride
27 Metformin in Co-morbid Diabetes or Prediabetes and Serious Mental Illness Completed NCT02167620 Phase 4 Metformin;Placebo
28 Cardiovascular Effects of GLP-1 Receptor Activation Completed NCT03101930 Phase 4 Liraglutide;Sitagliptin;Placebos;Exendin (9-39)
29 The Effect of A-lipoic Acid (ALA) on Fatty Acid-induced Impairment of Glucose-stimulated Insulin Secretion Completed NCT01056497 Phase 4 alpha lipoic acid
30 Mechanisms Underlying Metabolic Syndrome in Obesity Completed NCT00579813 Phase 4 Pioglitazone
31 The Assessment of the Effect of Metformin and Its Serum Concentration on the Concentration of Substances Associated With the Production of Nitric Oxide in Patients With Impaired Carbohydrate Metabolism Completed NCT03398356 Phase 4 Metformin
32 MetfoRmin and Its Effects on Myocardial Dimension and Left Ventricular Hypertrophy in Normotensive Patients With Coronary Artery Disease Completed NCT02226510 Phase 4 Metformin XL;Placebo
33 Oral Cholecalciferol in Prevention of Type 2 DM in Prediabetic Population With Vitamin D Insufficiency Completed NCT01436916 Phase 4 oral cholecalciferol + life style counselling;placebo + life style counselling
34 A Multicentre, Open-labelled, Randomized, Controlled Study to Evaluate the Efficacy of Metformin in Preventing Diabetes in China. Completed NCT03441750 Phase 4 metformin
35 Effects of Metformin on Longevity Gene Expression and Inflammation and Prediabetic Individuals. A Placebo-controlled Trial Completed NCT01765946 Phase 4 Metformin;placebo
36 A Long-term, Multicentre, Double-blind, Randomised Parallel-group Trial to Determine Whether Reducing Post-prandial Glycaemia Can Reduce Cardiovascular-related Morbidity and Mortality in Patients With Established Coronary Heart Disease or Acute Coronary Syndrome Who Have Impaired Glucose Tolerance Completed NCT00829660 Phase 4 Acarbose;Matching Placebo
37 Postmarketing Clinical Study on AO-128 Completed NCT02287402 Phase 4 AO-128
38 The Effect of Exenatide on Body Weight, Energy Expenditure and Hunger in Obese Women Without Diabetes Mellitus Completed NCT00456885 Phase 4 exenatide;Placebo
39 Effect of Pioglitazone With and Without Exenatide on Body Weight, Fat Topography, Beta Cell Function, and Glycemic Control in Type 2 Diabetic Patients Completed NCT00845182 Phase 4 Pioglitazone;Exenatide;Pioglitazone and Exenatide
40 The Chronic and Acute Postprandial Vascular Effects of Exenatide vs. Metformin in Abdominally Obese Patients With Impaired Glucose Tolerance Completed NCT00546728 Phase 4 Exenatide;Metformin
41 Telmisartan vs. Losartan in Hypertensive Patients With Impaired Glucose Tolerance: A Comparison of Their Antihypertensive, Metabolic, and Vascular Effects Completed NCT00407862 Phase 4 Telmisartan 80 mg;Losartan 50 mg
42 Effects of GH and Pioglitazone in Viscerally Obese Adults With IGT Completed NCT00352287 Phase 4 Recombinant human growth hormone; pioglitazone
43 Efficacy and Safety of Nateglinide Treatment in Renal Treatment Recipients With Post Transplant Diabetes Mellitus or Impaired Glucose Tolerance Completed NCT00319189 Phase 4 Nateglinide
44 A Single Center, Open Label, Single Arm Trial To Evaluate The Effect Of Twenty Four Weeks Of Treatment With 80 Mg To 320 Mg Valsartan On Insulin Sensitivity In Subjects With Impaired Glucose Tolerance (Igt) Completed NCT00241072 Phase 4 valsartan
45 Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation Completed NCT00974272 Phase 4 Exenatide
46 Phase IV Study Evaluating the Effect of Sitagliptin (Januviaâ„¢) on Beta-cell Function in Patients With Acute Myocardial Infarction or Unstable Angina Pectoris and Newly Detected Impaired Glucose Tolerance or Type 2 Diabetes. Completed NCT00627744 Phase 4 Sitagliptin
47 Exercise in Elderly Individuals With Impaired Glucose Tolerance: Beneficial for Vasculature and Neurons? Completed NCT01219231 Phase 4
48 Effect of Exenatide on Brain Glucose Uptake in Relations to Pancreatic, Adipose Tissue, and Hepatic Function Completed NCT01588418 Phase 4 Exenatide;Placebo
49 The Effect of Korean Red Ginseng Supplementation on Glucose Control in Subjects With Impaired Fasting Glucose, Impaired Glucose Tolerance or Newly-diagnosed Type 2 Diabetes Mellitus Completed NCT01911663 Phase 4
50 Blood Pressure and Metabolic Effects of Nebivolol Compared With Hydrochlorothiazide and Placebo in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose Completed NCT00673790 Phase 4 Nebivolol with concomitant losartan or lisinopril;HCTZ with concomitant losartan or lisinopril;Placebo with concomitant losartan or lisinopril

Search NIH Clinical Center for Prediabetes Syndrome

Cochrane evidence based reviews: prediabetic state

Sources

Genetic Tests for Prediabetes Syndrome

About this section
Sources

Anatomical Context for Prediabetes Syndrome

About this section

Organs/tissues related to Prediabetes Syndrome:

MalaCards : Ovary, Heart, Kidney, Skin, Pancreatic Islet, Skeletal Muscle, Liver
Sources

Publications for Prediabetes Syndrome

About this section

Articles related to Prediabetes Syndrome:

(show top 50) (show all 19487)
# Title Authors PMID Year
1
A randomized controlled trial of Baduanjin exercise to reduce the risk of atherosclerotic cardiovascular disease in patients with prediabetes. 62 41
36369247 2022
2
Effectiveness of a 6-Month Nutrition Intervention in People Living with HIV and Prediabetes Progressing through Stages of Change towards Positive Health Behavior. 62 41
36429394 2022
3
Clinician perceptions of a clinical decision support system to reduce cardiovascular risk among prediabetes patients in a predominantly rural healthcare system. 62 41
36402988 2022
4
Defects in insulin secretion and action in the pathogenesis of type 2 diabetes mellitus. 53 62
20425581 2010
5
Alanine-aminotransferase levels predict impaired glucose tolerance in a worksite population. 53 62
19855923 2010
6
Metabolic syndrome and insulin resistance in Thai women with polycystic ovary syndrome. 53 62
20462081 2010
7
Mitochondrial dysfunction and lipotoxicity. 53 62
19782153 2010
8
Gene expression of PPARgamma and PGC-1alpha in human omental and subcutaneous adipose tissues is related to insulin resistance markers and mediates beneficial effects of physical training. 53 62
19966034 2010
9
Pancreatic fat is negatively associated with insulin secretion in individuals with impaired fasting glucose and/or impaired glucose tolerance: a nuclear magnetic resonance study. 53 62
20225188 2010
10
Effects of long-term calorie restriction and endurance exercise on glucose tolerance, insulin action, and adipokine production. 53 62
19904628 2010
11
Reduced plasma levels of glucagon-like peptide-1 in elderly men are associated with impaired glucose tolerance but not with coronary heart disease. 53 62
19936703 2010
12
Visceral fat is a strong predictor of insulin resistance regardless of cardiorespiratory fitness in non-diabetic people. 53 62
20495292 2010
13
Prevalence of diabetes mellitus and impaired glucose tolerance in patients with decompensated cirrhosis being evaluated for liver transplantation: the utility of oral glucose tolerance test. 53 62
20520971 2010
14
Metabolic syndrome and alanine aminotransferase: a global perspective from the NAVIGATOR screening population. 53 62
20002471 2009
15
Contribution of glucose tolerance and gender to cardiac adiposity. 53 62
19820028 2009
16
[TNF-alpha and insulin-resistance: metabolic effects of in vivo therapeutic blockade]. 53 62
20143002 2009
17
Maturity-onset diabetes of the young in children with incidental hyperglycemia: a multicenter Italian study of 172 families. 53 62
19564454 2009
18
Serum high-molecular weight adiponectin decreases abruptly after an oral glucose load in subjects with normal glucose tolerance or impaired fasting glucose, but not those with impaired glucose tolerance or diabetes mellitus. 53 62
19592051 2009
19
Variation in the UCP2 and UCP3 genes associates with abdominal obesity and serum lipids: the Finnish Diabetes Prevention Study. 53 62
19769793 2009
20
Retinol-binding protein 4 is associated with impaired glucose regulation and microalbuminuria in a Chinese population. 53 62
19506831 2009
21
Biological variation in fasting serum insulin-like growth factor binding protein-1 (IGFBP-1) among individuals with a varying glucose tolerance. 53 62
19463807 2009
22
Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. 53 62
19584347 2009
23
Evidence for association between polycystic ovary syndrome (PCOS) and TCF7L2 and glucose intolerance in women with PCOS and TCF7L2. 53 62
19351735 2009
24
Metabolic implications of dietary trans-fatty acids. 53 62
19584878 2009
25
Low levels of insulin-like growth-factor-binding protein-1 (IGFBP-1) are prospectively associated with the incidence of type 2 diabetes and impaired glucose tolerance (IGT): the Söderåkra Cardiovascular Risk Factor Study. 53 62
19297224 2009
26
Retinol-binding protein 4 is associated with impaired glucose tolerance but not with whole body or hepatic insulin resistance in Mexican Americans. 53 62
19190263 2009
27
Association between serum leptin and adiponectin levels with risk of insulin resistance and impaired glucose tolerance in non-diabetic women. 53 62
19419916 2009
28
Classical PKC is not associated with defective insulin signaling in patients with impaired glucose tolerance. 53 62
19124171 2009
29
RBP-to-retinol ratio, but not total RBP, is elevated in patients with type 2 diabetes. 53 62
19215278 2009
30
Association between C-reactive protein and pre-diabetic status in a Chinese Han clinical population. 53 62
19116941 2009
31
Leptin concentrations in patients with polycystic ovary syndrome before and after met-formin treatment depending on insulin resistance, body mass index and androgen con-centrations--introductory report. 53 62
19995720 2009
32
Serum resistin levels in critically ill patients are associated with inflammation, organ dysfunction and metabolism and may predict survival of non-septic patients. 53 62
19545363 2009
33
The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes. 53 62
19145587 2009
34
[Polymorphism of glucose intolerance and insulin resistance susceptibility genes in oncological patients]. 53 62
19140314 2008
35
Effect of intensive lifestyle intervention on C-reactive protein in subjects with impaired glucose tolerance and obesity. Results from a randomized controlled trial with 5-year follow-up. 53 62
19096961 2008
36
[The metabolic syndrome. Part II: its mechanisms of development and its complications]. 53 62
18936730 2008
37
[The role of leptin in polycystic ovary syndrome]. 53 62
19145943 2008
38
Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity. 53 62
18633104 2008
39
Association of impaired glucose metabolism in morbid obesity with hypoadiponectinaemia. 53 62
18777458 2008
40
High plasma retinol binding protein-4 and low plasma adiponectin concentrations are associated with severity of glucose intolerance in women with previous gestational diabetes mellitus. 53 62
18492757 2008
41
The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose tolerance. 53 62
18492770 2008
42
Differences in insulin action and secretion, plasma lipids and blood pressure levels between impaired fasting glucose and impaired glucose tolerance in Japanese subjects. 53 62
18957806 2008
43
Effect of the orlistat on serum endotoxin lipopolysaccharide and adipocytokines in South Asian individuals with impaired glucose tolerance. 53 62
18564278 2008
44
Adipokines and incident type 2 diabetes in an Aboriginal Canadian [corrected] population: the Sandy Lake Health and Diabetes Project. 53 62
18339973 2008
45
Absence of an acute insulin response predicts onset of type 2 diabetes in a Caucasian population with impaired glucose tolerance. 53 62
18460558 2008
46
Insulin resistance and impaired glucose tolerance in overweight and obese Costa Rican schoolchildren. 53 62
18693476 2008
47
Transgenic mice overexpressing neuropeptide Y in noradrenergic neurons: a novel model of increased adiposity and impaired glucose tolerance. 53 62
18276767 2008
48
Effect of N. sativa oil on impaired glucose tolerance and insulin insensitivity induced by high-fat-diet and turpentine-induced trauma. 53 62
18819546 2008
49
Retinol-binding protein 4 is associated with insulin resistance, but appears unsuited for metabolic screening in women with polycystic ovary syndrome. 53 62
18362299 2008
50
Leptin, soluble leptin receptor, adiponectin and resistin in relation to OGTT in overweight/obese postmenopausal women. 53 62
18468820 2008
Sources

Variations for Prediabetes Syndrome

About this section
Sources

Expression for Prediabetes Syndrome

About this section
Search GEO for disease gene expression data for Prediabetes Syndrome.
Sources

Pathways for Prediabetes Syndrome

About this section

Pathways related to Prediabetes Syndrome according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Signal Transduction 66
13.71 SERPINE1 PPARG LEP IRS1 INSR INS
2
PI3K-Akt signaling pathway 74
Show member pathways
 12.86 SLC2A4 IRS1 INSR INS IGF1
3
IL-9 Signaling Pathways 65
Show member pathways
 12.8 SLC2A4 RETN RBP4 LEP IRS1 INSR
4
Translation Insulin regulation of translation 22
Show member pathways
 12.7 SLC2A4 SERPINE1 IRS1 INSR INS IGF1
5
PPARA activates gene expression 66
Show member pathways
 12.46 SLC2A4 PPARG LEP ADIPOQ
6
Development Ligand-independent activation of ESR1 and ESR2 22
Show member pathways
 12.25 PPARG IRS1 INSR IGF1
7
Glucose / Energy Metabolism 3
12.24 SLC2A4 PPARG IRS1 INSR INS GCG
8
AMPK Enzyme Complex Pathway 64
Show member pathways
 12.16 INS INSR IRS1 LEP SLC2A4
9
AMP-activated protein kinase signaling 74
Show member pathways
 12.08 SLC2A4 LEP INSR INS ADIPOQ
10
Peptide hormone metabolism 66
Show member pathways
 12.08 DPP4 GCG GHRL IGF1 INS LEP
11
Gastrin signaling pathway 74
11.88 SERPINE1 PPARG IRS1
12
Senescence and autophagy in cancer 74
11.84 SERPINE1 INS IGF1
13
Overlap between signal transduction pathways contributing to LMNA laminopathies 74
Show member pathways
 11.79 SLC2A4 PPARG ADIPOQ
14
Regulation of beta-cell development 66
Show member pathways
 11.77 INS IAPP GCK
15
Mesenchymal Stem Cells and Lineage-specific Markers 65
11.71 SLC2A4 PPARG LEP INS IGF1 ADIPOQ
16
HIF-1-alpha transcription factor network 61
11.62 SERPINE1 LEP GCK
17
Incretin synthesis, secretion, and inactivation 66
Show member pathways
 11.56 LEP GCG DPP4
18
Development_Leptin signaling via PI3K-dependent pathway 22
11.5 SLC2A4 LEP IRS1
19
Signaling events mediated by PTP1B 61
11.47 LEP IRS1 INSR INS
20
Insulin Pathway 61
11.42 INS INSR IRS1
21
Adipogenesis 74
11.39 SLC2A4 SERPINE1 RETN PPARG LEP IRS1
22
Nonalcoholic fatty liver disease 74
11.38 LEP IRS1 INSR INS ADIPOQ
23
FOXA1 transcription factor network 61
11.34 INS GCG APOB
24
Leptin-insulin signaling overlap 74
Show member pathways
 11.24 LEP IRS1 INSR INS
25
Anti-diabetic Drug Potassium Channel Inhibitors Pathway, Pharmacodynamics 60
11.23 IRS1 INSR INS GCK
26
Differentiation of white and brown adipocyte 74
11.16 PPARG LEP ADIPOQ
27
Type II diabetes mellitus 74
11.08 SLC2A4 IRS1 INSR ADIPOQ
28
Roles of ceramides in the development of insulin resistance 74
11.05 SLC2A4 IRS1 INSR INS
29
Antipsychotics Pathway (Metabolic Side Effects), Pharmacodynamics 60
11.04 LEP INS GHRL
30
Insulin-mediated glucose transport 61
11.01 SLC2A4 INSR INS
31
Insulin signaling in adipocytes (diabetic condition) 74
Show member pathways
 10.95 SLC2A4 IRS1 INSR
32
Transcription factor regulation in adipogenesis 74
10.78 SLC2A4 PPARG LEP IRS1 INSR ADIPOQ
33
SCFA and skeletal muscle substrate metabolism 74
10.4 SLC2A4 GCG
Sources

GO Terms for Prediabetes Syndrome

About this section

Cellular components related to Prediabetes Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.07 ADIPOQ APOB CRP DPP4 GCG GHRL
2 extracellular space GO:0005615 9.7 SERPINE1 RETN RBP4 LEP INS IGF1
3 insulin receptor complex GO:0005899 9.56 IRS1 INSR
4 vesicle membrane GO:0012506 9.55 SLC2A4 GAD1 APOB

Biological processes related to Prediabetes Syndrome according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell population proliferation GO:0008284 10.37 LEP IRS1 INSR INS IGF1 DPP4
2 positive regulation of MAPK cascade GO:0043410 10.15 GHRL IAPP IGF1 INS INSR LEP
3 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 10.14 LEP INSR INS IGF1
4 positive regulation of protein kinase B signaling GO:0051897 10.13 LEP INSR INS IGF1 IAPP
5 response to activity GO:0014823 10.09 ADIPOQ GCG LEP
6 regulation of insulin secretion GO:0050796 10.08 GCG GCK LEP
7 positive regulation of insulin secretion GO:0032024 10.06 CAPN10 GCK GHRL RBP4
8 activation of protein kinase B activity GO:0032148 10.04 IGF1 INS INSR
9 positive regulation of mitotic nuclear division GO:0045840 10.03 IGF1 INS INSR
10 glucose metabolic process GO:0006006 10.02 LEP INS GHRL GCK ADIPOQ
11 positive regulation of insulin receptor signaling pathway GO:0046628 10 INS IRS1 LEP
12 positive regulation of glycolytic process GO:0045821 9.99 INSR INS IGF1
13 negative regulation of gluconeogenesis GO:0045721 9.97 INS GCK ADIPOQ
14 positive regulation of glycogen biosynthetic process GO:0045725 9.96 GCK IGF1 INS INSR IRS1
15 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.95 PPARG CRP ADIPOQ
16 positive regulation of adipose tissue development GO:1904179 9.93 PPARG GHRL
17 positive regulation of glucose import GO:0046326 9.93 IRS1 INSR INS IGF1 CAPN10 ADIPOQ
18 positive regulation of respiratory burst GO:0060267 9.92 INSR INS
19 bone mineralization involved in bone maturation GO:0035630 9.9 LEP IGF1
20 positive regulation of fatty acid metabolic process GO:0045923 9.89 PPARG ADIPOQ
21 negative regulation of feeding behavior GO:2000252 9.88 RETN INS
22 positive regulation of developmental growth GO:0048639 9.88 LEP INSR
23 negative regulation of lipid storage GO:0010888 9.88 PPARG LEP CRP
24 cellular response to insulin stimulus GO:0032869 9.86 ADIPOQ CAPN10 GCK INSR IRS1 LEP
25 negative regulation of acute inflammatory response GO:0002674 9.79 PPARG INS
26 cellular response to prostaglandin stimulus GO:0071379 9.72 PPARG APOB
27 glucose homeostasis GO:0042593 9.62 SLC2A4 RBP4 PPARG LEP IRS1 INSR

Molecular functions related to Prediabetes Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 10 SERPINE1 LEP IAPP GCG DPP4 ADIPOQ
2 insulin receptor binding GO:0005158 9.63 IRS1 INS IGF1
3 insulin-like growth factor receptor binding GO:0005159 9.56 IRS1 INSR INS IGF1
4 hormone activity GO:0005179 9.5 RETN LEP INS IGF1 IAPP GHRL
Sources

Sources for Prediabetes Syndrome

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....